Hydrogen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Hydrogen
Accession Number
DB15127
Description

Hydrogen is under investigation in clinical trial NCT02830854 (Molecular Hydrogen for Cognitive Function and Performance in Elderly).

Type
Small Molecule
Groups
Investigational
Purchasing individual compounds or compound libraries for your research?
Learn More
Synonyms
  • MOLECULAR HYDROGEN

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
7YNJ3PO35Z
CAS number
1333-74-0
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
Not Available
RxNav
5497
Wikipedia
Hydrogen

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentCoronary Artery Disease (CAD) / Percutaneous Coronary Intervention (PCI)1
3CompletedTreatmentOnychomycosis1
3Not Yet RecruitingTreatmentAstrocytomas / Low Grade Glioma (LGG) / Recurrent WHO Grade II Glioma1
3RecruitingTreatmentAstrocytomas / Low Grade Glioma (LGG)1
3RecruitingTreatmentLow Grade Glioma (LGG) / Neurofibromatosis Type 1 / Visual Pathway Glioma1
3Unknown StatusTreatmentEvidence of Liver Transplantation1
2Active Not RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma / Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma / Recurrent Childhood Central Nervous System Neoplasm / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Malignant Solid Neoplasm / Recurrent Neuroblastoma / Refractory Malignant Solid Neoplasm / Refractory Neuroblastoma / Refractory Non-Hodgkin's lymphoma / Refractory Primary Central Nervous System Neoplasm1
2Active Not RecruitingTreatmentBorderline Ovarian Serous Tumor / Low Grade Ovarian Serous Adenocarcinoma / Micropapillary Serous Carcinoma / Primary Peritoneal Carcinoma / Primary Peritoneal Low Grade Serous Adenocarcinoma / Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor1
2Active Not RecruitingTreatmentKRAS NP_004976.2:p.G12R / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage IV Pancreatic Cancer AJCC v6 and v71
2Not Yet RecruitingTreatmentCutaneous Neurofibromas / Neurofibromatosis Type 11

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 08:52 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates